MedTrace Logo

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

NCT02847624 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1802

Last updated 2025-12-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.

Conditions

  • Polycystic Kidney, Autosomal Dominant

Interventions

DRUG

tolvaptan

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yasuhiko Fukuta, PhD · Otsuka Pharmaceutical Co., Ltd.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-24
Primary Completion
2022-09-20
Completion
2022-09-20

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02847624 on ClinicalTrials.gov